Clinical trial · Interventional
Weight Bearing Exercise in Preventing Frailty in Stage I-IIIA Breast Cancer Survivors
Prevention of Frailty in Breast Cancer Survivors: A Pilot Study
NCT03708055CI-TRIAL-00035404completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial studies how well weight bearing exercise works in preventing frailty in stage I-IIIA breast cancer survivors. Weight bearing exercise, including muscle-strengthening, aerobic, flexibility, and balance exercises, can decrease fat and increase muscle, which may lead to reduced frailty.
Conditions
Conditions (17)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anatomic Stage IA Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Anatomic Stage IB Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Anatomic Stage I Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Anatomic Stage IIA Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Anatomic Stage IIB Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Anatomic Stage II Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Anatomic Stage IIIA Breast Cancer AJCC v8 | — | UNRESOLVED | — |
| Cancer Survivor | — | UNRESOLVED | — |
| Overweight | — | UNRESOLVED | — |
| Postmenopausal | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise Intervention | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prevention (weight bearing exercise program)
- description
- Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
- interventionNames
- Behavioral: Exercise Intervention
Primary outcomes (4)
- measure
- Reproducibility of muscle activation by subcutaneous fat mass measures.
- timeFrame
- Up to 9 years
- description
- Demonstrate reproducibility of forearm muscle activation and subcutaneous fat measures in a healthy convenience sample/population (N= 10). Standard anthropometric measurements (height, weight, waist, hip and arm circumferences) will be taken at baseline and 8weeks. A total body dual energy X-ray absorptiometry (DXA) scan, with an effective radiation dose of about 0.01 mSv, which is about the same as background radiation in one day according to the American College of Radiology (http://www.radiologyinfo.org/en/safety/index.cfm?pg=sfty\_xray#3), will be used to determine fat mass and fat free mass at these same time-points. Skeletal muscle mass will be determined by using both appendicular lean mass/height2 method and the residuals model from the Health ABC Study.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 37 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Post-menopausal (12 months without menstrual period: naturally, surgically, by hormone suppression). * History of early stage breast cancer (stage I, II, IIIa). * At least 6 months from chemotherapy. * May be receiving hormonal therapy during the study. * Currently disease-free, including a negative mammogram within 1 year. * Body mass index (BMI) between 25 and 40kg/m\^2. * In general good health with no acute or chronic disease that could worsen with weight bearing exercise. * Not currently on a prescribed diet nor reporting weight loss of \> 10 pounds (lbs) in previous 3 months. * Not currently participating in physical activity (PA) independently or a structured program (performing \< 120 min of low-intensity, low-impact exercise per week; and no weightlifting or similar physical activity). * Ability to participate in physical activity, not limited by severe disability (e.g., severe arthritic conditions); chronic back pain, or history or presence of diseases for which increased physical activity would not be advised. * No severe chronic disease, other than breast cancer (e.g., human immunodeficiency virus/acquired immunodeficiency syndrome \[HIV/AIDS\], kidney failure, liver failure, chronic obstructive pulmonary disease, congestive heart failure, Alzheimer?s, unstable angina, uncontrolled asthma, uncontrolled diabetes, uncontrolled hypertension). * No implanted cardiac pacemaker, cardiac defibrillator, or other implanted electronic medical equipment. * No history of drug or alcohol abuse. * Able to remain in a lying or sitting position for an extended period (\> 30 minutes). * No history or presence of a significant psychiatric disorder or any other condition that would interfere with participation in the trial. * Medical clearance by treating physician. * Willing to discontinue nonsteroidal antiinflammatory drug (NSAID) use, except Tylenol and baby aspirin (80mg), 1 week prior to blood draws. * Willing to maintain body weight during the study. * Can be reached by telephone. * Willing to complete consent process and sign informed consent form.
References
Publications (0)
Data not yet available
No reference posted for this study.